TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes

BACKGROUND: TLR9 agonists are being developed as immunotherapy against malignancies and infections. TLR9 is primarily expressed in B cells and plasmacytoid dendritic cells (pDCs). TLR9 signalling may be critically important for B cell activity in lymph nodes but little is known about the in vivo imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Schleimann, Mariane H., Kobberø, Maria-Louise, Vibholm, Line K., Kjær, Kathrine, Giron, Leila B., Busman-Sahay, Kathleen, Chan, Chi Ngai, Nekorchuk, Michael, Schmidt, Manuel, Wittig, Burghardt, Damsgaard, Tine E., Ahlburg, Peter, Hellfritzsch, Michel B., Zuwala, Kaja, Rothemejer, Frederik H., Olesen, Rikke, Schommers, Phillipp, Klein, Florian, Dweep, Harsh, Kossenkov, Andrew, Nyengaard, Jens R., Estes, Jacob D., Abdel-Mohsen, Mohamed, Østergaard, Lars, Tolstrup, Martin, Søgaard, Ole S., Denton, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642412/
https://www.ncbi.nlm.nih.gov/pubmed/31300344
http://dx.doi.org/10.1016/j.ebiom.2019.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642412/
https://www.ncbi.nlm.nih.gov/pubmed/31300344
http://dx.doi.org/10.1016/j.ebiom.2019.07.005

Ejemplares similares